Well, investors, NuVasive (NUVA +0.00%) just couldn't wait to tell you the good news. Ahead of its presentation at the JPMorgan Healthcare Conference and its official Q4 earnings press release, the company revealed its full year 2012 revenue results. In this video, health care analyst Max Macaluso discusses why this news drove shares up by more than 10% and what investors should watch in 2013.
1 Medical Device Preview Investors Were Hoping For
By Max Macaluso – Jan 9, 2013 at 2:43PM
NASDAQ: NUVA
NuVasive
Good news today at NuVasive.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo